Adaptive Biotechnologies Corporation (ADPT)

NASDAQ: ADPT · IEX Real-Time Price · USD
12.12
-0.50 (-3.96%)
At close: Aug 11, 2022 4:00 PM
12.00
-0.12 (-0.99%)
Pre-market: Aug 12, 2022 7:28 AM EDT
-3.96%
Market Cap 1.81B
Revenue (ttm) 159.68M
Net Income (ttm) -232.12M
Shares Out 148.99M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,684,173
Open 12.74
Previous Close 12.62
Day's Range 12.04 - 13.21
52-Week Range 5.96 - 40.00
Beta 0.98
Analysts Buy
Price Target 15.61 (+28.8%)
Earnings Date Aug 3, 2022

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients wi... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Jun 27, 2019
CEO Chad Robins
Employees 858
Stock Exchange NASDAQ
Ticker Symbol ADPT
Full Company Profile

Financial Performance

In 2021, ADPT's revenue was $154.34 million, an increase of 56.88% compared to the previous year's $98.38 million. Losses were -$207.28 million, 41.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 15.61, which is an increase of 28.80% from the latest price.

Price Target
$15.61
(28.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 7.50% and 0.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...

Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?

Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in ...

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: Should You Buy?

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system...

Why Adaptive Biotechnologies Shares Are Rising

Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease. Adaptive Biotechnologies says, in...

Adaptive Biotechnologies launches T cell-based test for Lyme disease

Adaptive Biotechnologies unveiled a new type of test Wednesday for Lyme disease that may be most useful at detecting disease during the early stages of infection.

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests T-Detect Lyme enables patients and healthcare providers to detec...

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Stand...

Data demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes Data demonstrate growing utilization of MRD to identify deep responses associated with th...

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

SEATTLE, May 26, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...

10 Amazing Stocks Under $10 (Part II)

Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.

Other symbols: BBIODNAFUBOHIMXMSFT

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Lags Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies reports $38.6M in Q1 revenue as it repositions following job cuts

Adaptive Biotechnologies announced its first quarter earnings Wednesday, two months after laying off 12% of its workforce.

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste...

Cathie Wood Can't Get Enough of These 2 Biotech Stocks

The CEO of Ark Invest hasn't given up on these risky biotech stocks.

Other symbols: BNR

Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans

Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's MRD business includes clonoSEQ d...

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to...

The company reiterates full year 2022 guidance The company reiterates full year 2022 guidance

Adaptive Biotechnologies lays off about 100 people, 12% of headcount, to ‘streamline our workforce'

Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned.

Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...

Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associa...

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

Adaptive Biotechnologies revenue rises 57% in 2021 to $154.3M

Adaptive Biotechnologies, which develops technology to assess the immune response, posted $154.